Article · 26 Sep 2025
ArticlePublished 26 Sep 2025
Licensing biosimilars challenges and opportunities in a growing market
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
As the patents for blockbuster biologic drugs expire, biosimilars— biologic medicines that are highly similar to existing reference products— are poised to reshape the pharmaceutical landscape. Offering comparable efficacy and safety at reduced costs, biosimilars present a compelling opportunity to expand access to life-saving treatments. However, their path to market is fraught with regulatory, scientific, and commercial challenges. Licensing biosimilars effectively requires navigating a complex web of global standards, market dynamics, and evolving technologies.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.
More from this journal
The newest in Health Economics & Outcome Research: Open Access.
Article · 26 Sep 2025
Breaking down the fda approval process what every pharma innovator should know
Article · 26 Sep 2025
Inside a licensing agreement key clauses that shape pharma partnerships
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalHealth Economics & Outcome Research: Open Access
- SubjectBusiness & Management
- SubjectNursing & Healthcare
- BylineArticles whose byline prints “Okeya James”
